Current Medimmune management has little R&D experience and is floundering getting new drugs through the pipeline and before the approval agencies. Medimmune was purchased by AZN for $15+ billion.
James Young, Novavax chair, BOD, does have the know how. Hum.
All I know is that Medimmune has been a major disappointment for AstraZeneca. For $15 billion dollars, they only squeezed out a few drugs. Synagis is going to expire 4Q 2015. All of the guys at Novavax knows everything about MedImmune from working there. If you are going to lose Synagis to generics, and Motavizumab completely failed...and your RSV pipeline look like junk (which it does)...then what are your options? The longer AZN waits, the sweeter the price will be. Take your time and mull it over.
I'm willing to take a $2 billion offer. Chump change compared to MedImmune.
bballgm, thanks for the info. I think a $2 billion offer is way too low considering how effective nvax products are. What would nvax stock price be priced at if a $10 billion offer? I'm no geek when it comes to math crunching.
LOL. I'll take one, two, three billion dollars, whatever they agree on. But, I'm hoping it will be $3 billion because that's about $20/share, which I've been calling for for five years.
I'm going to be the laughing stock of this board if we got less than $20.
Hey lou.king, What did I say about someome from AZN on LinkedIn working at both their company and Novavax (Yes I posted it and yes you have called me the biggest fool. Get lost low life). A transaction behind closed doors though is wrong. Jim Young needs to step up now and deliver for the shareholder.